Bisphosphonates target B cells to enhance humoral immune responses.

Published

Journal Article

Bisphosphonates are a class of drugs that are widely used to inhibit loss of bone mass in patients. We show here that the administration of clinically relevant doses of bisphosphonates in mice increases antibody responses to live and inactive viruses, proteins, haptens, and existing commercial vaccine formulations. Bisphosphonates exert this adjuvant-like activity in the absence of CD4(+) and γδ T cells, neutrophils, or dendritic cells, and their effect does not rely on local macrophage depletion, Toll-like receptor signaling, or the inflammasome. Rather, bisphosphonates target directly B cells and enhance B cell expansion and antibody production upon antigen encounter. These data establish bisphosphonates as an additional class of adjuvants that boost humoral immune responses.

Full Text

Duke Authors

Cited Authors

  • Tonti, E; Jiménez de Oya, N; Galliverti, G; Moseman, EA; Di Lucia, P; Amabile, A; Sammicheli, S; De Giovanni, M; Sironi, L; Chevrier, N; Sitia, G; Gennari, L; Guidotti, LG; von Andrian, UH; Iannacone, M

Published Date

  • October 31, 2013

Published In

Volume / Issue

  • 5 / 2

Start / End Page

  • 323 - 330

PubMed ID

  • 24120862

Pubmed Central ID

  • 24120862

Electronic International Standard Serial Number (EISSN)

  • 2211-1247

Digital Object Identifier (DOI)

  • 10.1016/j.celrep.2013.09.004

Language

  • eng

Conference Location

  • United States